Wells Fargo & Company MN trimmed its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 45.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,343,459 shares of the life sciences company’s stock after selling 1,124,433 shares during the quarter. Wells Fargo & Company MN owned approximately 1.72% of Integra LifeSciences Holdings Corporation worth $73,231,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. LS Investment Advisors LLC boosted its stake in Integra LifeSciences Holdings Corporation by 90.7% in the first quarter. LS Investment Advisors LLC now owns 2,412 shares of the life sciences company’s stock valued at $102,000 after acquiring an additional 1,147 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Integra LifeSciences Holdings Corporation by 223.6% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock valued at $107,000 after acquiring an additional 1,751 shares during the last quarter. Turner Investments LLC purchased a new position in Integra LifeSciences Holdings Corporation in the first quarter valued at about $126,000. Elkfork Partners LLC boosted its stake in Integra LifeSciences Holdings Corporation by 121.2% in the first quarter. Elkfork Partners LLC now owns 3,212 shares of the life sciences company’s stock valued at $135,000 after acquiring an additional 1,760 shares during the last quarter. Finally, Pitcairn Co. purchased a new position in Integra LifeSciences Holdings Corporation in the second quarter valued at about $207,000. Hedge funds and other institutional investors own 85.28% of the company’s stock.

In other Integra LifeSciences Holdings Corporation news, Director Donald E. Morel, Jr. acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 4th. The shares were bought at an average price of $49.25 per share, with a total value of $492,500.00. Following the completion of the acquisition, the director now owns 29,612 shares in the company, valued at approximately $1,458,391. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Donald E. Morel, Jr. acquired 2,500 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The stock was acquired at an average cost of $49.29 per share, for a total transaction of $123,225.00. Following the acquisition, the director now owns 29,612 shares of the company’s stock, valued at approximately $1,459,575.48. The disclosure for this purchase can be found here. In the last three months, insiders purchased 17,550 shares of company stock worth $864,842. 21.50% of the stock is currently owned by insiders.

A number of research firms have weighed in on IART. Oppenheimer Holdings, Inc. set a $60.00 target price on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research note on Saturday, June 24th. UBS AG reiterated a “buy” rating and issued a $60.00 target price (up from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research note on Friday, June 9th. Raymond James Financial, Inc. boosted their target price on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, July 27th. Zacks Investment Research cut shares of Integra LifeSciences Holdings Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, June 28th. Finally, Cantor Fitzgerald set a $65.00 target price on shares of Integra LifeSciences Holdings Corporation and gave the company a “buy” rating in a research note on Wednesday, July 26th. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $53.54.

COPYRIGHT VIOLATION NOTICE: “Integra LifeSciences Holdings Corporation (IART) Shares Sold by Wells Fargo & Company MN” was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/15/integra-lifesciences-holdings-corporation-iart-shares-sold-by-wells-fargo-company-mn.html.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at 52.21 on Friday. The company’s 50 day moving average is $50.39 and its 200-day moving average is $48.32. Integra LifeSciences Holdings Corporation has a 52 week low of $37.71 and a 52 week high of $56.42. The stock has a market capitalization of $4.08 billion, a PE ratio of 63.67 and a beta of 0.73.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.45. The company had revenue of $282.16 million for the quarter, compared to the consensus estimate of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The firm’s revenue was up 13.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.40 earnings per share. On average, equities analysts predict that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current year.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.